VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
LUCD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
LUCDLucid Diagnostics Inc.
$1.05$107M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksLUCDBalance Sheet

Lucid Diagnostics Inc. (LUCD) Balance Sheet

8Y historyFree accessUpdated daily

The company's capital structure appears increasingly fragile, evidenced by a debt-to-equity ratio that surged to 6.70 in 2026Q1 alongside a shrinking equity base of $4.0 million.

LUCD Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Total Current Assets31.36M37.47M25.15M22.07M24.36M57.3M1.44M390.9K17.8K
Cash & Short-Term Investments27.88M34.7M22.36M18.9M22.47M53.66M111K156.4K17.8K
Cash Only27.88M34.7M22.36M18.9M22.47M53.66M111K156.4K17.8K
Short-Term Investments000000000
Accounts Receivable689K643K405K45K17K200K000
Days Sales Outstanding40.0849.8734.016.7616.46146---
Inventory1M353K341K278K111K493K834K00
Days Inventory Outstanding4.52K17.0815.0611.9711.21307.6---
Other Current Assets1.49M001.98M000118.09K0
Total Non-Current Assets2.72M2.98M5.57M5.2M8.15M1.7M755K643K0
Property, Plant & Equipment2.5M2.62M3.7M2.64M3.6M971K000
Fixed Asset Turnover0.01x1.80x1.17x0.92x0.10x0.51x---
Goodwill000000000
Intangible Assets210K315K736K1.42M3.44M0000
Long-Term Investments000000000
Other Non-Current Assets10K47K1.13M1.13M1.11M725K755K643K0
Total Assets34.08M40.45M30.71M27.27M32.51M59M2.19M1.03M17.8K
Asset Turnover0.12x0.12x0.14x0.09x0.01x0.01x---
Asset Growth %184.37%31.68%12.63%-16.12%-44.9%2587.88%112.3%5708.43%-
Total Current Liabilities29.39M28.58M23.52M29.38M8.43M4.26M15.71M6.34M1.08M
Accounts Payable1.08M970K1.24M1.15M1.06M1.49M2.06M799.08K497.23K
Days Payables Outstanding46.0946.9454.849.34106.65929.66---
Short-Term Debt26.11M24M18.6M13.95M00000
Deferred Revenue (Current)000936K00000
Other Current Liabilities2.2M2.04M1.35M791K5.53M557K05.32M583.26K
Current Ratio1.07x1.31x1.07x0.75x2.89x13.45x0.09x0.06x0.02x
Quick Ratio1.03x1.30x1.05x0.74x2.88x13.34x0.04x0.06x0.02x
Cash Conversion Cycle4.51K20.01-5.73-30.6-78.98-476.06---
Total Non-Current Liabilities695K927K1.8M199K1.04M0000
Long-Term Debt000000000
Capital Lease Obligations4.16M927K1.8M199K1.04M0000
Deferred Tax Liabilities000000000
Other Non-Current Liabilities000000000
Total Liabilities30.08M29.51M25.32M29.58M9.46M4.26M15.71M6.34M1.08M
Total Debt26.8M25.82M21.25M15.26M2M0000
Net Debt-1.07M-8.88M-1.1M-3.64M-20.48M-53.66M-111K-156.4K-17.8K
Debt / Equity6.70x2.36x3.94x-0.09x----
Debt / EBITDA-0.55x--------
Net Debt / EBITDA0.02x--------0.03x
Interest Coverage-2160.10x-2256.36x-1750.12x-125.60x-7021.38x-41.61x---
Total Equity4M10.94M5.39M-2.31M23.05M54.74M-13.52M-5.31M-1.06M
Equity Growth %534.07%102.86%333.28%-110.03%-57.9%504.93%-154.61%-399.61%-
Book Value per Share0.040.110.11-0.060.641.52-0.37-0.14-0.03
Total Shareholders' Equity4M10.94M5.39M-2.31M23.05M54.74M-13.52M-5.31M-1.06M
Common Stock165K131K63K42K41K35K14K14.11K10K
Retained Earnings-297.96M-274.33M-203.77M-150.74M-98.08M-41.9M-13.83M-5.55M-1.13M
Treasury Stock000000000
Accumulated OCI000000000
Minority Interest000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Capital structure insolvency risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Deteriorating Capital Base and Solvency

As reported in recent financial statements, Lucid Diagnostics' equity base has experienced extreme volatility, contracting from $25.8 million in 2025Q3 to just $4.0 million by 2026Q1, signaling a precarious trajectory that leaves the company with minimal cushion against its persistent and substantial operating losses.

The rapid erosion of shareholder equity suggests that the company is consuming its capital base to fund ongoing commercialization efforts rather than building intrinsic value. Investors should monitor whether this trend of equity depletion necessitates further dilutive financing, which appears increasingly likely given the current burn rate.

Leverage Burden Amidst Operational Losses

Based on the provided balance sheet data, the company's debt-to-equity ratio surged to 6.70 in 2026Q1, reflecting a reliance on debt financing that appears unsustainable given the absence of positive operating cash flow to service these obligations or support the underlying capital structure.

The escalation in leverage metrics indicates that debt is being utilized as a survival mechanism rather than a strategic growth tool. This reliance on debt in a high-burn environment warrants investigation into potential refinancing risks and the impact of interest expenses on future liquidity.

Tightening Liquidity and Cash Runway

According to quarterly filings, the company's cash position dropped to $27.9 million in 2026Q1 from $47.3 million in 2025Q4, indicating that the current liquidity buffer is rapidly diminishing relative to the scale of the company's ongoing operational cash requirements and high fixed-cost structure.

A current ratio hovering near 1.07 suggests that the company possesses little margin for error in managing its short-term liabilities. The narrowing gap between cash reserves and operational burn implies that the firm may face significant liquidity constraints in the near term without a capital infusion.

Asset Quality and Valuation Distortions

As indicated by the historical balance sheet, the company's asset composition is heavily skewed by intangible assets and volatile cash balances, with net PPE remaining relatively stagnant at $2.5 million, which may suggest that the firm's physical infrastructure is not scaling in proportion to its capital expenditures.

The discrepancy between reported asset values and the company's inability to generate positive margins suggests that the balance sheet may overstate the utility of its current infrastructure. Analysts should consider whether the carrying value of these assets remains appropriate given the persistent lack of commercial traction.

LUCD — Frequently Asked Questions

Quick answers to the most common questions about buying LUCD stock.

What are the total assets of Lucid Diagnostics Inc. (LUCD)?

As of 2025, Lucid Diagnostics Inc. (LUCD) had total assets of $40.4M including $37.5M in current assets.

How much debt does Lucid Diagnostics Inc. (LUCD) have?

Lucid Diagnostics Inc. (LUCD) carries total debt of $25.8M, offset by $34.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Lucid Diagnostics Inc.?

Lucid Diagnostics Inc. (LUCD) has total shareholders' equity (book value) of $10.9M ($0.11 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Lucid Diagnostics Inc.'s current ratio and liquidity?

Lucid Diagnostics Inc. (LUCD) reported a current ratio of 1.31x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.